Bios Life has launched with $25 million in seed funding and a partnership with Tempus, focusing on cancer surveillance for survivors and high-risk individuals. The company plans to create a virtual clinic that combines software, genomics, and direct patient care to continuously monitor cancer risk, moving away from traditional periodic screenings. With a team drawn from BioNTech and significant backing from prominent investors, Bios Life aims to provide personalized care using AI-enhanced tools and extensive oncology datasets. The initiative is seen as a potential game changer in improving cancer care and monitoring, especially for the over 40 million people in the U.S. living with or at risk for cancer.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://itbrief.co.uk/story/bios-life-emerges-with-usd-25-million-seed-tempus-deal
